Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A pill for multiple sclerosis (MS) that spares patients from needing injections has been approved for use on the NHS.
The National Institute for Health and Care Excellence (Nice) has given the green light to teriflunomide (also called Aubagio) for relapsing-remitting MS, which is thought to account for about 85% of all new cases of the disease.
Manufactured by Genzyme, t he once-a-day anti-inflammatory means patients no longer have to turn to painful injections to prevent relapses. Side-effects of injections can also include flu-like symptoms.
http://news.uk.msn.com/nhs-approval-for-new-ms-pill
The National Institute for Health and Care Excellence (Nice) has given the green light to teriflunomide (also called Aubagio) for relapsing-remitting MS, which is thought to account for about 85% of all new cases of the disease.
Manufactured by Genzyme, t he once-a-day anti-inflammatory means patients no longer have to turn to painful injections to prevent relapses. Side-effects of injections can also include flu-like symptoms.
http://news.uk.msn.com/nhs-approval-for-new-ms-pill